Observational data in dialysis patients has indicated an increased cardiovascular mortality. One pathophysiological cause of this cardiovascular mortality in these patients is volume overload. In addition, an inappropriately activated renin—angiotensin system (RAS) has been proposed as another possible mechanism for the increased cardiovascular mortality. With these possible causes in mind, blockade of the RAS with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) have both emerged as means of preventing cardiovascular events in this population. This review focuses on clinical evidence of the beneficial effects of ACE inhibitors and ARBs in dialysis patients with regard to the improvement of cardiovascular events as well as blood pressure control and maintenance of dialysis therapy.
Agarwal, R., Lewis, R., Davis, J.L. and Becker, B. ( 2001) Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis38: 1245-1250.
2.
Allon, M. ( 1993) Treatment and prevention of hyperkalemia in end-stage renal disease. Kidney Int43: 1197-1209.
3.
Bolanos, L., Castro, P., Falcon, T.G., Mouzo, R. and Varela, J.M. ( 2002) Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol22: 67-72.
4.
Buter, H., Navis, G.Y., Woittiez, A.J., de Zeeuw, D. and de Jong, P.E.(1999) Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol54: 953-958.
5.
Cannella, G., Paoletti, E., Delfino, R., Peloso, G., Molinari, S. and Traverso, G.B. ( 1993) Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int44: 881-886.
6.
Cannella, G., Paoletti, E., Delfino, R., Peloso, G., Rolla, D. and Molinari, S. ( 1997) Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis30: 659-664.
7.
Charron, R.C., Leme, C.E., Wilson, D.R., Ing, T.S. and Wrong, O.M. ( 1969) The effect of adrenal steroids on stool composition, as revealed by in vivo dialysis of faeces. Clin Sci37: 151-167.
8.
Chew, C.G., Weise, M.D. and Disney, A.P. ( 1999) The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant14: 2047-2049.
9.
Collins, A.J., Roberts, T.L., St Peter, W.L., Chen, S.C., Ebben, J. and Constantini, E. ( 2002) United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines . Am J Kidney Dis39: 784-795.
10.
De Rosa, M.L., Cardace, P., Rossi, M., Baiano, A. and de Cristofaro, A. ( 2002) Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens16: 133-140.
11.
DeLong, M., Logan, J.L., Yong, K.C. and Lien, Y.H. ( 2005) Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance . Nephrol Dial Transplant20: 585-590.
12.
Dobbie, J.W. ( 1992) Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int12: 14-27.
13.
Dyadyk, A.I., Bagriy, A.E., Lebed, I.A., Yarovaya, N.F., Schukina, E.V. and Taradin, G.G. ( 1997) ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant12: 945-951.
14.
Ecder, T., Edelstein, C.L., Chapman, A.B., Johnson, A.M., Tison, L., Gill, E.A. et al. (1999) Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant14: 1113-1116.
15.
Efrati, S., Zaidenstein, R., Dishy, V., Beberashvili, I., Sharist, M., Averbukh, Z. et al. (2002) ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis40: 1023-1029.
16.
Fang, W., Oreopoulos, D.G. and Bargman, J.M. ( 2008) Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant23: 3704-3710.
17.
Ferrario, C.M. ( 2006) Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension47: 515-521.
18.
Ferrario, C.M. and Strawn, W.B. ( 2006) Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol98: 121-128.
19.
Ferrario, C.M., Trask, A.J. and Jessup, J.A. ( 2005) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol289: H2281-2290.
20.
Gaddam, K.K. and Oparil, S. ( 2008) Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Curr Opin Nephrol Hypertens17: 484-490.
21.
Guerin, A.P., Blacher, J., Pannier, B., Marchais, S.J., Safar, M.E. and London, G.M. ( 2001) Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation103: 987-992.
22.
Guerin, A.P., Marchais, S.J., Metivier, F. and London, G.M. ( 2005) Arterial structural and functional alterations in uraemia . Eur J Clin Invest35(Suppl. 3): 85-88.
23.
Han, S.W., Won, Y.W., Yi, J.H. and Kim, H.J. ( 2007) No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant22: 1150-1155.
24.
Hatch, M. and Freel, R.W. ( 2008) Increased colonic sodium absorption in rats with chronic renal failure is partially mediated by AT1 receptor agonism. Am J Physiol Gastrointest Liver Physiol295: G348-356.
25.
Hatch, M., Freel, R.W. and Vaziri, N.D. ( 1998a) Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure. Am J Physiol274: F275-282.
26.
Hatch, M., Freel, R.W. and Vaziri, N.D. ( 1998b) Losartan antagonism of angiotensin-II-induced potassium secretion across rat colon. Pflugers Arch436: 717-724.
27.
Herzog, C.A., Ma, J.Z. and Collins, A.J. ( 2002) Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation105: 1336-1341.
28.
Hirakata, H., Iseki, K., Onoyama, K., Kumagai, H., Fujimi, S. and Omae, T. ( 1983) Long-term hemodynamic response to captopril (SQ 14,225) in hypertensive hemodialysis patients. Clin Nephrol19: 87-91.
29.
Hirakata, H., Onoyama, K., Iseki, K., Omae, T., Fujimi, S. and Kawahara, Y. ( 1981) Captopril (SQ 14225) clearance during hemodialysis treatment . Clin Nephrol16: 321-323.
30.
Ichihara, A., Hayashi, M., Kaneshiro, Y., Takemitsu, T., Homma, K., Kanno, Y. et al. (2005) Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis45: 866-874.
31.
Igarashi, Y., Suzuki, H., Imafuku, T., Saito, I. and Saruta, T. ( 1987) Hypertension in patients on chronic hemodialysis: the role of the renin-angiotensin system. Jpn Circ J51: 479-484.
32.
Imai, H., Nakamoto, H., Ishida, Y., Yamanouchi, Y., Inoue, T., Okada, H. et al. (2001) Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum. Adv Perit Dial17: 20-24.
33.
Kammerl, M.C., Schaefer, R.M., Schweda, F., Schreiber, M., Riegger, G.A. and Kramer, B.K. ( 2000) Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? Clin Nephrol53: 486-488.
34.
Kanno, Y., Takenaka, T., Nakamura, T. and Suzuki, H. ( 2006) Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol1: 730-737.
35.
Kessler, M., Zannad, F., Lehert, P., Grunfeld, J.P., Thuilliez, C., Leizorovicz, A. et al. (2007) Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study. Nephrol Dial Transplant22: 3573-3579.
36.
Kimura, G., Takahashi, N., Kawano, Y., Inenaga, T., Inoue, T., Nakamura, S. et al. (1995) Plasma renin activity in hemodialyzed patients during long-term follow-up. Am J Kidney Dis25: 589-592.
37.
Knoll, G.A., Sahgal, A., Nair, R.C., Graham, J., van Walraven, C. and Burns, K.D.(2002) Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med112: 110-114.
38.
Li, P.K., Chow, K.M., Wong, T.Y., Leung, C.B. and Szeto, C.C. ( 2003) Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med139: 105-112.
39.
London, G.M. ( 2001) Vascular disease and atherosclerosis in uremia. Blood Purif19: 139-142.
40.
London, G.M. ( 2005) Vascular disease and atherosclerosis in uremia. Nefrologia25(Suppl. 2): 91-95.
41.
Losito, A., Kalidas, K., Santoni, S., Ceccarelli, L. and Jeffery, S. ( 2002) Polymorphism of renin-angiotensin system genes in dialysis patients-association with cerebrovascular disease. Nephrol Dial Transplant17: 2184-2188.
42.
Luik, A.J., van Kuijk, W.H., Spek, J., de Heer, F., van Bortel, L.M., Schiffers, P.M. et al. (1997) Effects of hypervolemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients. Am J Kidney Dis30: 466-474.
43.
Macdougall, I.C. ( 1999) The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant14: 1836-1841.
44.
Matsumoto, N., Ishimitsu, T., Okamura, A., Seta, H., Takahashi, M. and Matsuoka, H. ( 2006) Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res29: 253-260.
45.
McCullough, P.A., Sandberg, K.R., Yee, J. and Hudson, M.P. ( 2002) Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst3: 188-191.
46.
McLaughlin, N., Gehr, T.W. and Sica, D.A. ( 2004) Aldosterone-receptor antagonism and end-stage renal disease . Curr Hypertens Rep6: 327-330.
47.
Meeus, F., Kourilsky, O., Guerin, A.P., Gaudry, C., Marchais, S.J. and London, G.M. ( 2000) Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int Suppl76: S140-147.
48.
Musini, V.M., Fortin, P.M., Bassett, K. and Wright, J.M. ( 2008) Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst RevCD007066.
49.
Ottosson, P., Attman, P.O., Agren, A.C. and Samuelsson, O. ( 2003) Candesartan cilexetil in haemodialysis patients. Clin Drug Investig23: 545-550.
50.
Paoletti, E., Cassottana, P., Bellino, D., Specchia, C., Messa, P. and Cannella, G. ( 2002) Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors . Am J Kidney Dis40: 728-736.
51.
Pfister, M., Schaedeli, F., Frey, F.J. and Uehlinger, D.E. ( 1999) Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Br J Clin Pharmacol47: 645-651.
52.
Phakdeekitcharoen, B. and Leelasa-nguan, P. ( 2004) Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis44: 738-746.
53.
Raizada, V., Skipper, B., Luo, W., Garza, L., Hines, C.W., Harford, A.A. et al. (2005) Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease. Kidney Int68: 1186-1189.
54.
Roithinger, F.X., Punzengruber, C., Wallner, M., Ulbrich, W., Pachinger, O., Kramar, R. et al. (1994) The influence of ACE-inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. Clin Nephrol42: 309-314.
55.
Rostoker, G., Griuncelli, M. and Benmaadi, A. ( 2006) Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients. Ren Fail28: 283-286.
56.
Ruiz-Ortega, M., Ruperez, M., Esteban, V., Rodriguez-Vita, J., Sanchez-Lopez, E., Carvajal, G. et al. (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant21: 16-20.
57.
Sandle, G.I., Gaiger, E., Tapster, S. and Goodship, T.H. ( 1987) Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond) 73: 247-252.
58.
Saracho, R., Martin-Malo, A., Martinez, I., Aljama, P. and Montenegro, J. ( 1998) Evaluation of the Losartan in Hemodialysis (ELHE) Study . Kidney Int Suppl68: S125-129.
59.
Schaefer, R.M., Schaefer, L. and Horl, W.H. ( 1994) Anaphylactoid reactions during hemodialysis. Clin Nephrol42(Suppl. 1): S44-47.
60.
Schiffl, H. and Lang, S.M. ( 1999) Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease. Nephron81: 106-108.
61.
Shibasaki, Y., Masaki, H., Nishiue, T., Nishikawa, M., Matsubara, H. and Iwasaka, T. ( 2002) Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron90: 256-261.
62.
Suzuki, H., Kanno, Y., Kaneko, K., Kaneko, M., Kotaki, S., Mimura, T. et al. (2004) Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial8: 320-327.
63.
Suzuki, H., Kanno, Y., Sugahara, S., Ikeda, N., Shoda, J., Takenaka, T. et al. (2008) Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis52: 501-506.
64.
Suzuki, H., Kanno, Y., Sugahara, S., Okada, H. and Nakamoto, H. ( 2004) Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis43: 1056-1064.
65.
Suzuki, H., Nakamoto, H., Okada, H., Sugahara, S. and Kanno, Y. ( 2003) A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial19: 59-66.
66.
Takahashi, A., Takase, H., Toriyama, T., Sugiura, T., Kurita, Y., Ueda, R. et al. (2006) Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant21: 2507-2512.
67.
Tepel, M., van der Giet, M. and Zidek, W. ( 2001) Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes. Kidney Blood Press Res24: 71-74.
68.
Toto, R., Shultz, P., Raij, L., Mitchell, H., Shaw, W., Ramjit, D. et al. (1998) Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. Hypertension31: 684-691.
69.
Wauters, J.P., Waeber, B., Brunner, H.R., Guignard, J.P., Turini, G.A. and Gavras, H. ( 1981) Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol16: 86-92.
70.
Weidmann, P., Maxwell, M.H., Lupu, A.N., Lewin, A.J. and Massry, S.G. ( 1971) Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med285: 757-762.
71.
Wetmore, J.B., Johansen, K.L., Sen, S., Hung, A.M. and Lovett, D.H. ( 2006) An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Hum Genet120: 201-210.
72.
Yu, W.C., Lin, Y.P., Lin, I.F., Chuang, S.Y. and Chen, C.H. ( 2006) Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis47: 478-484.
73.
Zannad, F., Kessler, M., Lehert, P., Grunfeld, J.P., Thuilliez, C., Leizorovicz, A. et al. (2006) Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int70: 1318-1324.
74.
Zheng, S., Nath, V. and Coyne, D.W. ( 2007) ACE inhibitor-based, directly observed therapy for hyper- ht tension in hemodialysis patients. Am J Nephrol27: 522-529.
